MiNK Therapeutics shared a post on LinkedIn:
“At SITC25, we reported new data showing that agenT-797, our off-the-shelf allo-iNKT cell therapy, delivers durable responses and immune reactivation in patients with PD-1–refractory solid tumors.
Patients across multiple hard-to-treat cancers experienced deep, lasting remissions—some extending beyond two years—along with a favorable safety profile and evidence of tumor-immune remodeling.
These results reinforce iNKT cells as a promising new therapeutic class and support advancing agenT-797 into Phase 2 development.
Read the release.
Review the poster.”
More Posts Featuring MiNK Therapeutic.